Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results
GlobeNewswire, Inc.
Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access...
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
GlobeNewswire, Inc.
The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming...
Bionano Reports Second Quarter 2026 Results and Provides a Business Update
GlobeNewswire, Inc.
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2026. "Our second quarter results reflect a strong vote of confidence from our routine use...
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
GlobeNewswire, Inc.
Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward starting clinical study for SG293 in...
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
GlobeNewswire, Inc.
One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-free weight...
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
GlobeNewswire, Inc.
Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for...
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
GlobeNewswire, Inc.
TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
GlobeNewswire, Inc.
Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and available-for-sale marketable securities as...
Varonis to Present at Upcoming Investor Conference
GlobeNewswire, Inc.
MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), the data and AI security leader, announced its participation at the following upcoming conference: Citi's 2026 Global TMT Conference, September 8 – 10, in New York. The...
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
GlobeNewswire, Inc.
Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash...
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
GlobeNewswire, Inc.
Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 Million Expected to Support...
INTUIT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intuit Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INTU
GlobeNewswire, Inc.
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intuit Inc. (NASDAQ: INTU) between August 22, 2025 and May 20, 2026, inclusive (the “Class Period”), of the...
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against GPGI, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit - GPGI
GlobeNewswire, Inc.
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of GPGI, Inc. f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO) Class A common stock between November 3, 2025 and May 6, 2026, all dates inclusive...
NANO-X DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Nano-X Imaging Ltd. Investors to Secure Counsel Before Important August 11 Deadline in Securities Class Action – NNOX
GlobeNewswire, Inc.
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026, inclusive (the “Class Period”),...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
GlobeNewswire, Inc.
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) between December 27, 2024 and July 8, 2025,...
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Capricor Therapeutics, Inc. (CAPR) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire, Inc.
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates...
ROSEN, A NATIONALLY RANKED INVESTOR RIGHTS FIRM, Encourages EquipmentShare.com Inc Investors to Secure Counsel Before Important Deadline in Securities Class Action - EQPT
GlobeNewswire, Inc.
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of EquipmentShare.com Inc (NASDAQ: EQPT): (i) Class A common stock pursuant and/or traceable to the registration statement and...
INSULET DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD
GlobeNewswire, Inc.
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”),...
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that EquipmentShare.com, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - EQPT
GlobeNewswire, Inc.
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of EquipmentShare.com, Inc. (NASDAQ: EQPT): (i) Class A common stock pursuant and/or traceable to the registration...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Smartsheet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SMAR
GlobeNewswire, Inc.
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of sellers of Smartsheet Inc. (NYSE: SMAR) common stock between June 1, 2024 and September 23, 2024,...
Sign up for:
Global Business Watch
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.